Patents by Inventor Eloisa Lopez-Calle
Eloisa Lopez-Calle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12194466Abstract: A medical system for determining an analyte quantity in a blood sample via a cartridge that spins around a rotational axis. The cartridge may include: a separation chamber that separates blood plasma from the sample; a processing chamber containing a reagent with a specific binding partner which binds to the analyte to form an analyte specific binding partner complex; a first valve structure connecting the separation chamber to the processing chamber; a measurement structure to measure the quantity of the analyte, wherein the measurement structure includes a chromatographic membrane with an immobilized binding partner for direct or indirect binding of the analyte or the analyte specific binding partner complex, and an absorbent structure that is nearer to the axis than the membrane; a second valve structure connecting the processing chamber to the measurement structure; and a fluid chamber filled with a washing buffer and fluidically connected to the measurement structure.Type: GrantFiled: April 13, 2021Date of Patent: January 14, 2025Assignee: Roche Diagnostics Operations, Inc.Inventors: Christoph Boehm, Thorsten Brueckner, Thomas Fischer, Eloisa Lopez-Calle, Sascha Lutz, Josef Roedl, Juergen Spinke, Pamela Espindola, Thomas Manuel Keller, Thomas Dolbinow, Sabrina Adler, Erik Beiersdorf, Domenik Wensorra
-
Patent number: 11796540Abstract: The disclosure includes a method for determining an analyte in a sample in an interaction assay, including contacting a sample with an interaction modulator, wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM), aminodextran, carboxymethyldextran, Poly-(2-acrylamido-2-methyl-1-propanesulfonic acid (PAMPS), triethylamine, triethanolamine, taurine, or dodecylsulfate. The disclosure includes a method for determining an analyte in an interaction assay, including contacting the sample with an interaction modulator, wherein the interaction modulator is an enhancer of the interaction assay at low analyte concentrations and is a retarder of the interaction assay at high analyte concentrations and wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM) and/or Polyacrylic acid (PAA). The disclosure further relates to a kit having a detection agent specifically detecting an analyte and at least one interaction modulator.Type: GrantFiled: July 26, 2019Date of Patent: October 24, 2023Assignee: Roche Diagnostics Operations, Inc.Inventors: Georg Kurz, Eloisa Lopez-Calle, Ewelina Hegel, Josef Roedl, Eva Hoess, Joerg Kaufmann, Marisa Kirchenbauer
-
Patent number: 11391655Abstract: The present disclosure relates to an in vitro method for releasing analytes from a sample involving contacting the sample with (i) a chaotropic agent, (ii) an organic solvent, (iii) a detergent, and (iv) at least one agent providing bicarbonate ions. The present disclosure further relates to a release agent for releasing analytes from a sample having the aforesaid compounds. Moreover, the present disclosure relates to uses, kits, methods and devices related to the method and the release agent of the present disclosure.Type: GrantFiled: September 13, 2019Date of Patent: July 19, 2022Assignee: Roche Diagnostics Operations, Inc.Inventors: Eloisa Lopez-Calle, Ewelina Hegel, Thomas Fischer, Caroline Bylda, Hans-Peter Josel, Josef Roedl
-
Patent number: 11215577Abstract: A test system for analyzing a sample of a bodily fluid is provided and comprises: at least one test strip comprising at least one capillary channel comprising an inlet opening configured to receive the sample; a vent opening configured to provide an air vent to the capillary channel; and at least one zone consisting of a detection zone and a reagent zone; at least one measuring device configured for interacting with the test strip, the measuring device comprising at least one sealing element for hermetically sealing the vent opening from an ambient atmosphere; and at least one suction device adapted to provide an underpressure to the vent opening; wherein the measuring device further comprises at least one valve or is connectable to the valve, wherein the valve is configured to vent the vent opening of the test strip when the measuring device interacts with the test strip.Type: GrantFiled: November 9, 2018Date of Patent: January 4, 2022Assignee: Roche Diagnostics Operations, Inc.Inventors: Uwe Goebbert, EloĆsa Lopez-Calle, Michael Marquant, Christine Nortmeyer, Katja Reiter, Reiner Stein
-
Publication number: 20210229098Abstract: A medical system for determining an analyte quantity in a blood sample via a cartridge that spins around a rotational axis. The cartridge may include: a separation chamber that separates blood plasma from the sample; a processing chamber containing a reagent with a specific binding partner which binds to the analyte to form an analyte specific binding partner complex; a first valve structure connecting the separation chamber to the processing chamber; a measurement structure to measure the quantity of the analyte, wherein the measurement structure includes a chromatographic membrane with an immobilized binding partner for direct or indirect binding of the analyte or the analyte specific binding partner complex, and an absorbent structure that is nearer to the axis than the membrane; a second valve structure connecting the processing chamber to the measurement structure; and a fluid chamber filled with a washing buffer and fluidically connected to the measurement structure.Type: ApplicationFiled: April 13, 2021Publication date: July 29, 2021Inventors: Christoph Boehm, Thorsten Brueckner, Thomas Fischer, Eloisa Lopez-Calle, Sascha Lutz, Josef Roedl, Juergen Spinke, Pamela Espindola, Thomas Manuel Keller, Thomas Dolbinow, Sabrina Adler, Erik Beiersdorf, Domenik Wensorra
-
Patent number: 11000848Abstract: A medical system for determining an analyte quantity in a blood sample via a cartridge that spins around a rotational axis. The cartridge may include: a separation chamber that separates blood plasma from the sample; a processing chamber containing a reagent with a specific binding partner which binds to the analyte to form an analyte specific binding partner complex; a first valve structure connecting the separation chamber to the processing chamber; a measurement structure to measure the quantity of the analyte, wherein the measurement structure includes a chromatographic membrane with an immobilized binding partner for direct or indirect binding of the analyte or the analyte specific binding partner complex, and an absorbent structure that is nearer to the axis than the membrane; a second valve structure connecting the processing chamber to the measurement structure; and a fluid chamber filled with a washing buffer and fluidically connected to the measurement structure.Type: GrantFiled: May 17, 2018Date of Patent: May 11, 2021Assignee: Roche Diagnostics Operations, Inc.Inventors: Christoph Boehm, Thomas Dolbinow, Sabrina Adler, Erik Beiersdorf, Domenik Wensorra, Thorsten Brueckner, Thomas Fischer, Eloisa Lopez-Calle, Sascha Lutz, Josef Roedl, Juergen Spinke, Pamela Espindola, Thomas Manuel Keller
-
Patent number: 10864200Abstract: The present description relates to a liquid composition having at least one immune-modulatory macrolide compound and an essentially cell-free blood hemolysate. The present description further relates to a method for manufacturing a stabilized immune-modulatory macrolide calibration solution, by a) preparing a solution comprising an essentially cell-free blood hemolysate, b) admixing a predetermined amount of at least one immune-modulatory macrolide into said solution comprising an essentially cell-free blood hemolysate, and, thereby c) manufacturing a stabilized immune-modulatory macrolide calibration solution. Furthermore, the present description relates to kits, uses, devices, methods and to an immune-modulatory macrolide compound calibration solution related thereto.Type: GrantFiled: September 6, 2019Date of Patent: December 15, 2020Assignee: Roche Diagnostics Operations, Inc.Inventors: Ewelina Hegel, Hans-Peter Josel, Eloisa Lopez-Calle, Josef Roedl, Noah Weiss, Benjamin Tiemann
-
Patent number: 10809258Abstract: A method for determination of the amount of a specific analyte in a sample which may show a prozone effect by photometric assays, wherein the specific analyte is quantified from the change in the optical signal of the reaction mixture after the interaction of the analyte with analyte specific assay reagents. The optical signal is measured simultaneously for the specific analyte in the sample to be determined at the wavelength used for the determination of the analyte and at least at an additional specific wavelength used for the detection of the prozone effect over the complete reaction time. The reaction rate ratio R is calculated by using the signals obtained at the wavelength used for the detection of the prozone effect. By comparison of the calculated ratio value R with predetermined limit values it is judged if a prozone effect is present in the sample.Type: GrantFiled: February 12, 2016Date of Patent: October 20, 2020Assignee: Roche Diagnostics Operations, Inc.Inventors: Ewelina Hegel, Georg Kurz, Eloisa Lopez-Calle, Josef Roedl
-
Publication number: 20200003666Abstract: The present disclosure relates to an in vitro method for releasing analytes from a sample involving contacting the sample with (i) a chaotropic agent, (ii) an organic solvent, (iii) a detergent, and (iv) at least one agent providing bicarbonate ions. The present disclosure further relates to a release agent for releasing analytes from a sample having the aforesaid compounds. Moreover, the present disclosure relates to uses, kits, methods and devices related to the method and the release agent of the present disclosure.Type: ApplicationFiled: September 13, 2019Publication date: January 2, 2020Applicant: Roche Diagnostics Operations, Inc.Inventors: Eloisa Lopez-Calle, Ewelina Hegel, Thomas Fischer, Caroline Bylda, Hans-Peter Josel, Josef Roedl
-
Publication number: 20190388402Abstract: The present description relates to a liquid composition having at least one immune-modulatory macrolide compound and an essentially cell-free blood hemolysate. The present description further relates to a method for manufacturing a stabilized immune-modulatory macrolide calibration solution, by a) preparing a solution comprising an essentially cell-free blood hemolysate, b) admixing a predetermined amount of at least one immune-modulatory macrolide into said solution comprising an essentially cell-free blood hemolysate, and, thereby c) manufacturing a stabilized immune-modulatory macrolide calibration solution. Furthermore, the present description relates to kits, uses, devices, methods and to an immune-modulatory macrolide compound calibration solution related thereto.Type: ApplicationFiled: September 6, 2019Publication date: December 26, 2019Applicant: Roche Diagnostics Operations, Inc.Inventors: Ewelina Hegel, Hans-Peter Josel, Eloisa Lopez-Calle, Josef Roedl, Noah Weiss, Benjamin Tiemann
-
Publication number: 20190346439Abstract: The disclosure includes a method for determining an analyte in a sample in an interaction assay, including contacting a sample with an interaction modulator, wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM), aminodextran, carboxymethyldextran, Poly-(2-acrylamido-2-methyl-1-propanesulfonic acid (PAMPS), triethylamine, triethanolamine, taurine, or dodecylsulfate. The disclosure includes a method for determining an analyte in an interaction assay, including contacting the sample with an interaction modulator, wherein the interaction modulator is an enhancer of the interaction assay at low analyte concentrations and is a retarder of the interaction assay at high analyte concentrations and wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM) and/or Polyacrylic acid (PAA). The disclosure further relates to a kit having a detection agent specifically detecting an analyte and at least one interaction modulator.Type: ApplicationFiled: July 26, 2019Publication date: November 14, 2019Applicant: Roche Diagnostics Operations, Inc.Inventors: Georg Kurz, Eloisa Lopez-Calle, Ewelina Hegel, Josef Roedl, Eva Hoess, Joerg Kaufmann, Marisa Kirchenbauer
-
Patent number: 10288609Abstract: A method for determining the amount of a specific analyte by photometric assays, wherein the specific analyte in a sample reacts with an analyte specific reaction partner in a reaction mixture. At least two calibration curves are generated, the first calibration curve recorded at a first wavelength is optimized for low concentrations of the specific analyte thereby maximizing the lower detection limit and, the second calibration curve recorded at a second wavelength is optimized for high concentrations of the specific analyte thereby maximizing the upper detection limit. The optimized lower detection limit and the optimized upper detection limit results in an extended dynamic range.Type: GrantFiled: April 12, 2018Date of Patent: May 14, 2019Assignee: ROCHE DIAGNOSTICS OPERATIONS, INC.Inventors: Thorsten Brueckner, Eloisa Lopez-Calle, Norbert Oranth, Josef Roedl
-
Publication number: 20190079045Abstract: A test system for analyzing a sample of a bodily fluid is provided and comprises: at least one test strip comprising at least one capillary channel comprising an inlet opening configured to receive the sample; a vent opening configured to provide an air vent to the capillary channel; and at least one zone consisting of a detection zone and a reagent zone; at least one measuring device configured for interacting with the test strip, the measuring device comprising at least one sealing element for hermetically sealing the vent opening from an ambient atmosphere; and at least one suction device adapted to provide an underpressure to the vent opening; wherein the measuring device further comprises at least one valve or is connectable to the valve, wherein the valve is configured to vent the vent opening of the test strip when the measuring device interacts with the test strip.Type: ApplicationFiled: November 9, 2018Publication date: March 14, 2019Applicant: Roche Diagnostics Operations, Inc.Inventors: Uwe Goebbert, Eloisa Lopez-Calle, Michael Marquant, Christine Nortmeyer, Katja Reiter, Reiner Stein
-
Patent number: 10132805Abstract: A method for determining the amount of specific analyte of a sample which may show interferences by photometric assays, wherein the analyte is quantified from the change in the optical signal of the reaction mixture after the interaction of the analyte with analyte specific reagents. Multiple calibration curves are generated for multiple wavelengths for the specific analyte. An interference test is performed simultaneously to the determination of the specific analyte, for quantifying the amount of interfering substances present in the sample. The amount of each interfering substances is compared to predetermined cut-off values. The optical signal for the specific analyte is measured in the reaction mixture at multiple wavelengths over the complete reaction time, and a calibration curve is selected depending on the interfering substances. The amount of specific analyte is quantified by comparison with the selected calibration curve for the chosen wavelengths.Type: GrantFiled: October 27, 2014Date of Patent: November 20, 2018Assignee: Roche Diagnostics Operations, Inc.Inventors: Georg Kurz, Eloisa Lopez-Calle
-
Publication number: 20180264471Abstract: A medical system for determining an analyte quantity in a blood sample via a cartridge that spins around a rotational axis. The cartridge may include: a separation chamber that separates blood plasma from the sample; a processing chamber containing a reagent with a specific binding partner which binds to the analyte to form an analyte specific binding partner complex; a first valve structure connecting the separation chamber to the processing chamber; a measurement structure to measure the quantity of the analyte, wherein the measurement structure includes a chromatographic membrane with an immobilized binding partner for direct or indirect binding of the analyte or the analyte specific binding partner complex, and an absorbent structure that is nearer to the axis than the membrane; a second valve structure connecting the processing chamber to the measurement structure; and a fluid chamber filled with a washing buffer and fluidically connected to the measurement structure.Type: ApplicationFiled: May 17, 2018Publication date: September 20, 2018Inventors: Christoph Boehm, Thorsten Brueckner, Thomas Fischer, Eloisa Lopez-Calle, Sascha Lutz, Josef Roedl, Juergen Spinke, Pamela Espindola, Thomas Manuel Keller, Thomas Dolbinow, Sabrina Adler, Erik Beiersdorf, Domenik Wensorra
-
Publication number: 20180231544Abstract: A method for determining the amount of a specific analyte by photometric assays, wherein the specific analyte in a sample reacts with an analyte specific reaction partner in a reaction mixture. At least two calibration curves are generated, the first calibration curve recorded at a first wavelength is optimized for low concentrations of the specific analyte thereby maximizing the lower detection limit and, the second calibration curve recorded at a second wavelength is optimized for high concentrations of the specific analyte thereby maximizing the upper detection limit. The optimized lower detection limit and the optimized upper detection limit results in an extended dynamic range.Type: ApplicationFiled: April 12, 2018Publication date: August 16, 2018Applicant: Roche Diagnostics Operations, Inc.Inventors: Thorsten Brueckner, Eloisa Lopez-Calle, Norbert Oranth, Josef Roedl
-
Publication number: 20160161480Abstract: A method for determination of the amount of a specific analyte in a sample which may show a prozone effect by photometric assays, wherein the specific analyte is quantified from the change in the optical signal of the reaction mixture after the interaction of the analyte with analyte specific assay reagents. The optical signal is measured simultaneously for the specific analyte in the sample to be determined at the wavelength used for the determination of the analyte and at least at an additional specific wavelength used for the detection of the prozone effect over the complete reaction time. The reaction rate ratio R is calculated by using the signals obtained at the wavelength used for the detection of the prozone effect. By comparison of the calculated ratio value R with predetermined limit values it is judged if a prozone effect is present in the sample.Type: ApplicationFiled: February 12, 2016Publication date: June 9, 2016Inventors: Ewelina Hegel, Georg Kurz, Eloisa Lopez-Calle, Josef Roedl
-
Publication number: 20160145281Abstract: Novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, for example in the electrochemiluminescence based detection of an analyte.Type: ApplicationFiled: September 28, 2015Publication date: May 26, 2016Inventors: Robert Cysewski, Luisa de Cola, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Eloisa Lopez-Calle, Toralf Zarnt
-
Publication number: 20150044780Abstract: A method for determining the amount of specific analyte of a sample which may show interferences by photometric assays, wherein the analyte is quantified from the change in the optical signal of the reaction mixture after the interaction of the analyte with analyte specific reagents. Multiple calibration curves are generated for multiple wavelengths for the specific analyte. An interference test is performed simultaneously to the determination of the specific analyte, for quantifying the amount of interfering substances present in the sample. The amount of each interfering substances is compared to predetermined cut-off values. The optical signal for the specific analyte is measured in the reaction mixture at multiple wavelengths over the complete reaction time, and a calibration curve is selected depending on the interfering substances. The amount of specific analyte is quantified by comparison with the selected calibration curve for the chosen wavelengths.Type: ApplicationFiled: October 27, 2014Publication date: February 12, 2015Inventors: Georg Kurz, Eloisa Lopez-Calle
-
Publication number: 20150046114Abstract: A method for determining the amount of a specific analyte by photometric assays, wherein the specific analyte in a sample reacts with an analyte specific reaction partner in a reaction mixture. At least two calibration curves are generated, the first calibration curve recorded at a first wavelength is optimized for low concentrations of the specific analyte thereby maximizing the lower detection limit and, the second calibration curve recorded at a second wavelength is optimized for high concentrations of the specific analyte thereby maximizing the upper detection limit. The optimized lower detection limit and the optimized upper detection limit results in an extended dynamic range.Type: ApplicationFiled: October 27, 2014Publication date: February 12, 2015Inventors: Thornsten Brueckner, Eloisa Lopez-Calle, Norbert Oranth, Josef Roedl